Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679837 | 1.00 | TSHR (0.57) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL16681891 | 1.00 | TSHR (0.57) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL9208480 | 0.89 | TSHR (0.46) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL9208492 | 0.89 | TSHR (0.46) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL9446012 | 0.89 | TSHR (0.46) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL4609885 | 0.87 | TSHR (0.50) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL11341590 | 0.87 | TSHR (0.50) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL20490115 | 0.87 | TSHR (0.50) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL12315645 | 0.87 | PPARD (0.47) | TSHRPPARDTP53TDP1LPAR3 | |
| SCHEMBL11443334 | 0.85 | TSHR (0.48) | TSHRPPARDTP53TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292402-A | Method for synthesizing 3, 8-dimethyl-3, 5, 7-octatriene-1, 10-dialdehyde | 暨南大学 | 2021-08-24 | — | — | CN | claimed |
| EP-3086397-B1 | NONAQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING SAME, AND PHOSPHONOFORMIC ACID COMPOUND USED IN SAME | UBE INDUSTRIES (JP) | 2018-10-10 | — | — | EP | claimed |
| WO-1992015544-A1 | METHOD OF MAKING 2,7-DIMETHYL-2,4,6-OCTATRIENEDIAL AND DERIVATIVES THEREOF | LOYOLA UNIVERSITY OF CHICAGO (US) | 1992-09-17 | — | — | WO | claimed |
| US-5107030-A | Method of making 2,7-dimethyl-2,4,6-octatrienedial and derivatives thereof | LOYOLA UNIVERSITY OF CHICAGO (US) | 1992-04-21 | — | — | US | claimed |
| CN-113292402-A | Method for synthesizing 3, 8-dimethyl-3, 5, 7-octatriene-1, 10-dialdehyde | 暨南大学 | 2021-08-24 | — | — | CN | disclosed |
| EP-1667954-B1 | BIPOLAR TRANS CAROTENOID SALTS AND THEIR USES | DIFFUSION PHARMACEUTICALS LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| EP-1487774-B1 | BIPOLAR TRANS CAROTENOID SALTS AND THEIR USES | DIFFUSION PHARMACEUTICALS LLC (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-1487774-A4 | BIPOLAR TRANS CAROTENOID SALTS AND THEIR USES | Diffusion Pharmaceuticals LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170202798-A1 | BIPOLAR TRANS CARTENOID SALTS AND THEIR USES | DIFFUSION PHARMACEUTICALS LLC (US) | 2017-07-20 | — | — | US | disclosed |
| US-9604899-B2 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2017-03-28 | — | — | US | disclosed |
| US-20140051759-A1 | BIPOLAR TRANS CAROTENOID SALTS AND THEIR USES | DIFFUSION PHARMACEUTICALS LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8269027-B2 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2012-09-18 | — | — | US | disclosed |
| US-20070161610-A1 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1667954-A4 | BIPOLAR TRANS CAROTENOID SALTS AND THEIR USES | DIFFUSION PHARMACEUTICALS LLC (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1667954-A1 | BIPOLAR TRANS CAROTENOID SALTS AND THEIR USES | Diffusion Pharmaceuticals LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005028411-A1 | BIPOLAR TRANS CAROTENOID SALTS AND THEIR USES | DIFFUSION PHARMACEUTICALS LLC (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1487774-A2 | BIPOLAR TRANS CAROTENOID SALTS AND THEIR USES | Diffusion Pharmaceuticals LLC (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040116729-A1 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC | 2004-06-17 | — | — | US | disclosed |
| US-20040014725-A1 | Biopolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC | 2004-01-22 | — | — | US | disclosed |
| WO-2003072734-A2 | BIPOLAR TRANS CAROTENOID SALTS AND THEIR USES | DIFFUSION PHARMACEUTICALS LLC (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051759-A1 | BIPOLAR TRANS CAROTENOID SALTS AND THEIR USES | RBP4, MB, SLC6A12 | TSHR 1232/4885PPARD 1280/4885TP53 4467/4885 |
| US-20070161610-A1 | Bipolar trans carotenoid salts and their uses | RBP4, MB, SLC6A12 | TSHR 1232/4885PPARD 1280/4885TP53 4467/4885 |
| US-20170202798-A1 | BIPOLAR TRANS CARTENOID SALTS AND THEIR USES | TXNRD2, CYP11B2, CYP11B1 | TSHR 1403/4885PPARD 1048/4885TP53 4101/4885 |
| US-20040014725-A1 | Biopolar trans carotenoid salts and their uses | GYS1, TXNRD3, SLC39A14 | TSHR 2557/4885PPARD 1447/4885TP53 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.